Literature DB >> 23642575

International Work Group criteria for the diagnosis of Alzheimer disease.

Jeffrey L Cummings1, Bruno Dubois, José L Molinuevo, Philip Scheltens.   

Abstract

Alzheimer-type biomarker changes are identifiable in asymptomatic and mildly symptomatic predementia phases of Alzheimer disease (AD) and AD dementia. The International Work Group (IWG) guidelines for diagnosis identify a unified spectrum of 3 phases. The classic clinical feature that indicates AD is an episodic memory defect of the amnestic type. IWG criteria require biomarker support for the diagnoses of AD at any clinical stage. Pathophysiologic and topographic biomarkers are recognized. These criteria are proposed to allow highly specific diagnosis of AD and assist in identifying patients for clinical trials of AD-related treatments and other types of AD research.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23642575     DOI： 10.1016/j.mcna.2013.01.001

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN： 0025-7125            Impact factor:   5.456


  22 in total

Review 1.  Poor Gait Performance and Prediction of Dementia: Results From a Meta-Analysis.

Authors:  Olivier Beauchet; Cédric Annweiler; Michele L Callisaya; Anne-Marie De Cock; Jorunn L Helbostad; Reto W Kressig; Velandai Srikanth; Jean-Paul Steinmetz; Helena M Blumen; Joe Verghese; Gilles Allali
Journal:  J Am Med Dir Assoc       Date:  2016-02-04       Impact factor: 4.669

Review 2.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Michael Bauer; Harald Hampel; Sabine C Herpertz; Michael Soyka; Utako B Barnikol; Simone Lista; Emanuel Severus; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

3.  Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference.

Authors:  John E Morley; John C Morris; Marla Berg-Weger; Soo Borson; Brian D Carpenter; Natalia Del Campo; Bruno Dubois; Keith Fargo; L Jaime Fitten; Joseph H Flaherty; Mary Ganguli; George T Grossberg; Theodore K Malmstrom; Ronald D Petersen; Carroll Rodriguez; Andrew J Saykin; Philip Scheltens; Eric G Tangalos; Joe Verghese; Gordon Wilcock; Bengt Winblad; Jean Woo; Bruno Vellas
Journal:  J Am Med Dir Assoc       Date:  2015-09-01       Impact factor: 4.669

4.  Influence of controlled encoding and retrieval facilitation on memory performance in patients with different profiles of mild cognitive impairment.

Authors:  Roberta Perri; Marco Monaco; Lucia Fadda; Laura Serra; Camillo Marra; Carlo Caltagirone; Amalia C Bruni; Sabrina Curcio; M Bozzali; Giovanni A Carlesimo
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

5.  A test for Creutzfeldt-Jakob disease using nasal brushings.

Authors:  Christina D Orrú; Matilde Bongianni; Giovanni Tonoli; Sergio Ferrari; Andrew G Hughson; Bradley R Groveman; Michele Fiorini; Maurizio Pocchiari; Salvatore Monaco; Byron Caughey; Gianluigi Zanusso
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

6.  Dementia: Mild cognitive impairment--amyloid and beyond.

Authors:  Philip Scheltens
Journal:  Nat Rev Neurol       Date:  2013-07-23       Impact factor: 42.937

7.  Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease.

Authors:  Jonathan Vogelgsang; Hedieh Shahpasand-Kroner; Rebekka Vogelgsang; Frank Streit; Ruth Vukovich; Jens Wiltfang
Journal:  Exp Brain Res       Date:  2018-02-26       Impact factor: 1.972

8.  Gait phenotype from mild cognitive impairment to moderate dementia: results from the GOOD initiative.

Authors:  G Allali; C Annweiler; H M Blumen; M L Callisaya; A-M De Cock; R W Kressig; V Srikanth; J-P Steinmetz; J Verghese; O Beauchet
Journal:  Eur J Neurol       Date:  2015-12-14       Impact factor: 6.089

9.  Deep Learning-Based Multilevel Classification of Alzheimer's Disease Using Non-invasive Functional Near-Infrared Spectroscopy.

Authors:  Thi Kieu Khanh Ho; Minhee Kim; Younghun Jeon; Byeong C Kim; Jae Gwan Kim; Kun Ho Lee; Jong-In Song; Jeonghwan Gwak
Journal:  Front Aging Neurosci       Date:  2022-04-26       Impact factor: 5.702

10.  On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes.

Authors:  Michelle M Nuño; Joshua D Grill; Daniel L Gillen
Journal:  Clin Trials       Date:  2021-07-29       Impact factor: 2.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.